The National Human Rights Commission of Korea urged the Ministry of Health and Welfare on the need to expedite insurance listing of the CAR-T therapy ‘Kymriah’ that is used to treat leukemia and lymphoma.

The NHRC’s position is that the government should set a temporary drug price with NHI coverage for drugs that are directly related to life immediately upon its sale for the patients’ benefit. In this case, Kymriah will be again put on the agenda and discussed by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee on the 13th.

On the 12th, the NHRC turned down the complaint filed by leukemia patients and patients preparing to use Kymriah agai